Table 3.
Median serum hormone levels prior to treatment and following 12 weeks of LHRHa plus abiraterone.
| Median serum androgen |
Pre- treatment [90% CI] |
LHRHa + bicalutamide |
LHRHa + abiraterone [90% CI] |
% change (pre- treatment vs LHRHa + abiraterone) |
p-value |
|---|---|---|---|---|---|
| DHT (ng/dL) | 37.3 [31.3–74.4] |
6.6 | 0.98* [0.98-0.98] |
−97% | <0.001 |
| Testosterone (ng/dL) | 490.6 [397.4–586.9] |
19.4 | 0.49* [0.49-0.49] |
−99.9% | <0.001 |
| Androstenedione (ng/dL) | 71.5 [56.2–77.9] |
69.6 | 0.90 [0.68–2.37] |
−99% | <0.001 |
| DHEA (ng/dL) | 179.7 [128.1–292.2] |
386 | 16.9 [13.0–20.3] |
−91% | <0.001 |
| DHEA-S (µg/dL) | 130.2 [84.8–305.8] |
71.0 | 2.35 [0.44–3.04] |
−98% | <0.001 |
| Progesterone (ng/mL) | 0.05 [0.04–0.06] |
-- | 1.35 [0.74–1.84] |
+2600% | <0.001 |
| Pregnenolone (ng/mL) | 1.86 [1.60–2.97] |
-- | 10.9 [9.27–15.2] |
+486% | <0.001 |
*
indicates levels at the lower limit of detection; --indicates data not available